Durham, NCNCT06440707Now EnrollingIRB Ready

Stroke Clinical Trial in Durham, NC

Access cutting-edge stroke treatment through this phase 2 clinical trial at a research site in Durham. Study-provided care at no cost to qualified participants.

Sponsored by University of California, Los Angeles

Quick Self-Assessment

See if you qualify for this Durham location

Preparing your pre-screening questions…

Expert Care in Durham

Access stroke specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related stroke treatment provided free

Apply for This Durham Location

Check if you qualify for this stroke clinical trial in Durham, NC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Durham

    Convenient for NC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Durham site if eligible
  4. 4Begin participation

About This Stroke Study in Durham

Many patients with acute ischemic stroke are ineligible for currently available standard treatments (clot-busting medication, also known as intravenous thrombolytic or mechanical removal of a clot), and many are non-responders, resulting in a low rate of excellent outcomes, which necessitates the development of novel therapies. In this study, investigators are testing a new treatment in which a weak electrical current will be applied via scalp electrodes to increase collateral blood flow to the

Sponsor: University of California, Los Angeles

Who Can Participate

Inclusion Criteria

New focal neurologic deficit consistent with AIS
National Institute of Health Stroke Scale (NIHSS) ≥4 or NIHSS\< 4 in the presence of disabling deficit (a deficit that, if unchanged, would prevent the
patient from performing basic activities of daily living such as bathing, ambulating, toileting, hygiene, and eating or returning to work)
Presence of any cortical vessel occlusion, including Internal Carotid Artery, branches of Middle Cerebral Artery, Anterior Cerebral Artery, Posterior Cerebral Artery, Posterior-Inferior Cerebellar Artery
Presence of salvageable penumbra with perfusion lesion volume to ischemic core volume ratio of ≥ 1.2 on multimodal imaging
Patient ineligible for endovascular thrombectomy per American Heart/Stroke Associations Guidelines
Patient is able to be treated with tDCS within 24 hours of last known well time
A signed informed consent is obtained from the patient or patient's legally authorized representative Additional inclusion criteria for non-thrombolytic patients • Patient ineligible for IV lytics per American Heart/American Stroke Associations National Guidelines Additional inclusion criteria for thrombolytic receiving patients
Patient eligible for tPA per Guidelines
Within 2-hours from intravenous thrombolytic start of administration

Exclusion Criteria

Acute intracranial hemorrhage
Presence of MRI and gadolinium contraindications including cardiac implantable devices, cochlear implant, implanted neurostimulation device, unremovable metallic body piercing, magnetic dental implants, drug infusion pumps, estimated glomerular filtration rate of less than 35 mL/min/1.73 m2, allergy to gadolinium
Evidence of a large Ischemic core volume more than equal to 100 cc
Presence of transcranial direct current stimulation contraindications - electrically or magnetically activated intracranial metal and non-metal implants.
Signs or symptoms of acute myocardial infarction on admission
History of seizure disorder or new seizures with presentation of current stroke
Evidence of any other major life-threatening or serious medical condition that would prevent completion of the study protocol, including attendance at the 3-month follow-up visit
Concomitant experimental therapy
Preexisting scalp lesion at the site of the stimulation or presence of skull defects (may alter current flow
Preexisting coagulopathy
Patients suspected of having infective endocarditis and ischemic stroke related to septic emboli
Patients suspected or known to be infected with coronavirus 2019 (COVID-19)
Patient with radiographic evidence or suspicion of chronic conditions that may predispose them to intracranial hemorrhage, including brain arteriovenous malformations, cerebral cavernous malformations, cerebral telangiectasia, multiple previous intracerebral hemorrhages (amyloid angiopathy)
Suspected cerebral vasculitis based on medical history and imaging
Suspected cysticercosis
Suspected cranial dural arteriovenous fistula
Cerebral venous thrombosis
Head trauma causing loss of consciousness, concussion, confusion, or a headache within the past 30 days
Patient has suffered a hemorrhagic or ischemic stroke within the last three (3) months
History of cancer known to cause hemorrhagic metastases, e.g., melanoma, renal cell carcinoma,
choriocarcinoma, thyroid carcinoma, lung carcinoma, breast carcinoma, and hepatocellular carcinoma
History of left atrial myxoma
Evidence of dissection in the intracranial cerebral arteries
Suspicion of aortic dissection
Significant mass effect with midline shift
The patient is in a coma

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Durham?

Yes, this clinical trial (NCT06440707) has an active research site in Durham, NC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Stroke Treatment Options in Durham, NC

If you're searching for stroke treatment options in Durham, NC, this clinical trial (NCT06440707) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Durham research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced stroke specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all stroke clinical trials near you to find additional studies recruiting in your area.

More Stroke Trials in Durham, NC

See all stroke clinical trials recruiting in Durham — not just this study.

Browse Stroke Trials in Durham →

Browse More Trials by Condition

Stroke TrialsAll Conditions →

Ready to Join in Durham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Durham, NC